跳至主要内容
临床试验/CTRI/2021/07/034929
CTRI/2021/07/034929招募中未知

A prospective multi-centric randomized open label trial to assess efficacy of Hydroxychloroquine (HCQ) in reducing proteinuria in moderately severe primary IgA Nephropathy

one0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中
发起方
one

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Adult patients(=18 years AND <60 years age) with biopsy proven primary IgA nephropathy
  • 2.Persistent urinary protein creatinine ratio >1g/g but less than 3.5g/g
  • 3.eGFR=45 ml/min/1.73m2 as calculated by the chronic kidney disease epidemiology collaboration creatinine equation (CKD-EPI)
  • 4.Has been on ACEi/ARB therapy for at-least 6 months in maximal tolerated dose

排除标准

  • 1.Use of immunosuppression in the past 6 months
  • 2.IgAN requiring immunosuppression like crescentic IgAN or IgA vasculitis
  • 3.Current or planned pregnancy or lactation
  • 4.Concomitant systemic disease like diabetes, chronic liver disease, malignancy, any cardiac or cerebrovascular disease
  • 5.Retinopathy
  • 6.G6PD deficiency
  • 7.Unwilling to give consent

研究者

发起方
one

相似试验